Deliver Your News to the World

FDA Issues Complete Response Letter for Carisbamate


Titusville, NJ. -- The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.

The NDA, filed in October 2008 by Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) on behalf of Ortho-McNeil-Janssen Pharmaceuticals, Inc. seeks approval to market carisbamate (COMFYDE™) for the adjunctive treatment of partial onset seizures in patients 16 years of age and older.

The company is currently evaluating the FDA’s complete response letter, and will respond to the agency’s questions as quickly as possible.

About Partial Onset Seizures and Epilepsy
According to the Epilepsy Foundation, epilepsy is one of the most common disorders of the nervous system. It is defined by recurrent unprovoked seizures. It is categorized as “generalized” or “partial” depending on the location of the abnormal electrical activity in the brain that characterizes the disorder. Partial-onset seizures are common and are often difficult to treat. Partial-onset seizures are most often characterized by simple or complex repetitive movements, but virtually any sensory or emotional symptom can also occur as part of a partial seizure, including complex visual or auditory hallucinations. There are two categories of partial onset seizures: simple partial seizures (in which consciousness is retained), and complex partial seizures (in which consciousness is impaired or lost). Partial seizures can generalize and lead to tonic clonic seizures, during which the patient loses consciousness and is at risk for falling or injury.

About Carisbamate (COMFYDE ™)
Carisbamate has demonstrated anti-epileptic drug activity when given in addition to other AEDs in clinical trials. Although the precise mechanism of action remains to be elucidated, carisbamate modulates brain neuron activity and thereby reduces epileptic activity and seizures. Carisbamate has been studied in three placebo-controlled, double-blind clinical studies with most common adverse events of dizziness, headache, somnolence, nausea and fatigue.

Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a subsidiary of Johnson & Johnson, provides medicines for an array of health concerns, including central nervous system disorders, such as schizophrenia and epilepsy; metabolic diseases, such as diabetes; cardiovascular diseases; women’s health; urology; gastrointestinal; and infectious diseases. The company strives to provide innovative, high quality, safe and effective treatments and continually seeks new opportunities to offer solutions for unmet health care needs. Ortho-McNeil-Janssen Pharmaceuticals, Inc. is headquartered in Raritan, New Jersey.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.